JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB162816

Recombinant Human HIF Prolyl Hydroxylases protein (GST tag N-Terminus)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human HIF Prolyl Hydroxylases protein (GST tag N-Terminus) is a Human Full Length protein, in the 1 to 563 aa range, expressed in Wheat germ, suitable for ELISA, WB.

View Alternative Names

PH4, P4HTM, Transmembrane prolyl 4-hydroxylase, P4H-TM, Hypoxia-inducible factor prolyl hydroxylase 4, HIF-PH4, HIF-prolyl hydroxylase 4, HPH-4

1 Images
SDS-PAGE - Recombinant Human HIF Prolyl Hydroxylases protein (GST tag N-Terminus) (AB162816)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human HIF Prolyl Hydroxylases protein (GST tag N-Terminus) (AB162816)

ab162816 on a 12.5% SDS-PAGE stained with Coomassie Blue.

Key facts

Expression system

Wheat germ

Tags

GST tag N-Terminus

Applications

ELISA, WB

applications

Biologically active

No

Accession

Q9NXG6

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 0.79% Tris HCl, 0.31% Glutathione

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MAAAAVTGQRPETAAAEEASRPQWAPPDHCQAQAAAGLGDGEDAPVRPLCKPRGICSRAYFLVLMVFVHLYLGNVLALLLFVHYSNGDESSDPGPQHRAQGPGPEPTLGPLTRLEGIKVGHERKVQLVTDRDHFIRTLSLKPLLFEIPGFLTDEECRLIIHLAQMKGLQRSQILPTEEYEEAMSTMQVSQLDLFRLLDQNRDGHLQLREVLAQTRLGNGWWMTPESIQEMYAAIKADPDGDGVLSLQEFSNMDLRDFHKYMRSHKAESSELVRNSHHTWLYQGEGAHHIMRAIRQRVLRLTRLSPEIVELSEPLQVVRYGEGGHYHAHVDSGPVYPETICSHTKLVANESVPFETSCRQVSPNWGLPSILRPGTPMTQAQPCTVGVPLGMGPGDHWVIPVSPWEHPQLGTCSVPPLPYSYMTVLFYLNNVTGGGETVFPVADNRTYDEMSLIQDDVDLRDTRRHCDKGNLRVKPQQGTAVFWYNYLPDGQGWVGDVDDYSLHGGCLVTRGTKWIANNWINVDPSRARQALFQQEMARLAREGGTDSQPEWALDRAYRDARVEL","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":563,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Wheat germ","accessionNumber":"Q9NXG6","tags":[{"tag":"GST","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HIF prolyl hydroxylases also known as EglN or prolyl hydroxylase domain proteins (PHDs) are enzymes that modulate the stability of hypoxia-inducible factors (HIFs). These enzymes primarily facilitate the hydroxylation of prolyl residues on HIF-α subunits which marks them for degradation via the ubiquitin-proteasome pathway. Mammals express three isoforms: PHD1 PHD2 and PHD3 with PHD2 being the most widely studied. PHDs are expressed ubiquitously with higher levels observed in the liver kidneys and lung. The molecular mass of these enzymes is typically around 40 kDa.
Biological function summary

HIF prolyl hydroxylases play an essential role in oxygen sensing and homeostasis by regulating the activity of HIF-α subunits. Under normoxic conditions the hydroxylation of HIF-α by these hydroxylases permits recognition by the von Hippel-Lindau (VHL) protein leading to proteasomal degradation. In hypoxic conditions the decreased activity of HIF prolyl hydroxylases allows HIF-α stabilization and heterodimerization with HIF-β facilitating transcription of target genes involved in angiogenesis and metabolism. PHD2 is predominantly responsible for targeting HIF-1α.

Pathways

HIF prolyl hydroxylases integrate into the hypoxia response pathway. Oxygen-dependent regulation of HIF by these hydroxylases affects processes such as angiogenesis and erythropoiesis through interaction with several proteins including endothelial growth factor (VEGF) and erythropoietin (EPO). Beyond the hypoxia pathway they participate in metabolic pathways influencing cellular energy homeostasis thereby impacting proteins involved in metabolic regulation.

HIF prolyl hydroxylases associate with cancer and ischemic diseases. Dysregulation of these hydroxylases can lead to excessive stabilization of HIF-α which promotes tumor growth and metastasis due to enhanced angiogenesis and altered metabolism associated with cancer cells. In ischemic conditions reduced prolyl hydroxylases activity can offer protection by inducing adaptive responses through HIF-α stabilization. Their connectivity to the VHL protein further links them to von Hippel-Lindau disease characterized by tumor development in multiple organs.

Specifications

Form

Liquid

General info

Function

Catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates HIF1A at 'Pro-402' and 'Pro-564'. May function as a cellular oxygen sensor and, under normoxic conditions, may target HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination complex.

Post-translational modifications

Glycosylated.

Product protocols

Target data

Catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates HIF1A at 'Pro-402' and 'Pro-564'. May function as a cellular oxygen sensor and, under normoxic conditions, may target HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination complex.
See full target information P4HTM

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com